Funded Projects
Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.
Project # | Project Title | Research Focus Area | Research Program | Administering IC | Institution(s) | Investigator(s) | Location(s) | Year Awarded |
---|---|---|---|---|---|---|---|---|
1K99AR083486-01
Show Summary |
Novel Models to Study Dorsal Root Ganglion Neurons in Knee Osteoarthritis Pain | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NIAMS | STANFORD UNIVERSITY | BREWER, CHELSIE L | Stanford, CA | 2023 |
NOFO Title: HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (K99/R00 Independent Clinical Trial Not Allowed)
NOFO Number: RFA-NS-22-022 Summary: Knee osteoarthritis (OA) is a frequent cause of disability and chronic pain. Treatment often relies on analgesics like opioids to manage OA pain, with all the associated risks; other approaches to treat OA are often invasive and inaccessible to patients. Therefore, novel analgesic strategies are needed to reduce the high burden of knee OA-induced pain. This project aims to study in detail and target the sensory neurons that drive OA pain to assist in the development of more effective pain therapeutics. |
||||||||
1UG3NS134781-01
Show Summary |
A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease | Preclinical and Translational Research in Pain Management | Development and Optimization of Non-Addictive Therapies to Treat Pain | NINDS | IHP THERAPEUTICS, INC. | PADERI, JOHN | San Carlos, CA | 2023 |
NOFO Title: HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
NOFO Number: RFA-NS-21-010 |
||||||||
9SB1NS137964-04
Show Summary |
Advancing precision pain medicines to the clinic | Cross-Cutting Research | Small Business Programs | NINDS | NAVEGA THERAPEUTICS, INC. | MORENO, ANA MARIA (contact); ALEMAN GUILLEN, FERNANDO | San Diego, CA | 2023 |
NOFO Title: HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
NOFO Number: PAR-23-069 |
||||||||
4R33DA057683-02
Show Summary |
Leveraging regulatory flexibility for methadone take-home dosing to improve retention in treatment for opioid use disorder: A stepped-wedge randomized trial to facilitate clinic level changes | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | NEIGHBORS, CHARLES J (contact); BAO, YUHUA; RAMSEY, KELLY S | New York, NY | 2023 |
NOFO Title: HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-22-051 |
||||||||
1R01DA059471-01
Show Summary |
Medications for Opioid Use Disorder Differentially Modulate Intrinsically Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment | New Strategies to Prevent and Treat Opioid Addiction | Sleep Dysfunction as a Core Feature of Opioid Use Disorder and Recovery | NIDA | UNIVERSITY OF ALABAMA AT BIRMINGHAM | CROPSEY, KAREN L (contact); GAMBLE, KAREN L | Birmingham, AL | 2023 |
NOFO Title: HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional)
NOFO Number: RFA-DA-23-059 Summary: People who use opioids, as well as those who take medications approved by the U.S. Food and Drug Administration for opioid use disorder (OUD), report significant problems with sleep and biological rhythms. This project will explore the activity of a novel group of photosensitive neurons in the retinas, a potential source for sleep disturbances in these individuals. The research could lead to new treatment strategies and responses, but also may identify a non-invasive, circadian biomarker to predict recovery and relapse in people with OUD. |